Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

Inclusion Criteria

• •Histologically confirmed, soft-tissue sarcoma: excluding rhabdomyosarcoma (pleomorphic rhabdomyosarcoma patients are eligible), Ewing's, primitive neuroectodermal tumor (PNET), osteosarcoma, or gastrointestinal stromal tumor
• •American Joint Committee on Cancer (AJCC) (7th edition) stage IIb, III, or IV patients planned for resection of the primary tumor
• •* \> 5 cm in greatest dimension
• •* Intermediate or high-grade
• •* Superficial or deep
• •Sarcoma located on upper (includes shoulder) or lower (includes hip) extremities or on body wall
• •Intermediate or high-grade: grades 2 or 3 on scale of 1-3
• •Left ventricular ejection fraction (LVEF) \>= 50%
• •Absolute neutrophil count (ANC) \>= 1500/uL
• •Hemoglobin (Hgb) \>= 9.0 g/dL
• •Platelets \>= 100,000/uL
• •Creatinine =\< 1.5 x upper limit of normal (ULN)
• •Bilirubin =\< 1.5 mg/dL
• •Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 1.5 x ULN
• •International normalized ratio (INR) \< 1.5 or a prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits; patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate; for patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable
• •No prior chemotherapy, radiation, or biotherapy
• •No major surgery within 4 weeks prior to study entry
• •No contraindications to limb-sparing surgery; patient should be evaluated by a surgeon who specializes in sarcoma resections prior to study enrollment to ensure patient (pt) is a candidate for limb-sparing surgery
• •No severe peripheral vascular disease
• •Adequate contraception must be used and patients must not be pregnant or breastfeeding; women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation; men and women should use adequate birth control for at least thirty days after the last administration of sorafenib
• •Women of childbearing potential must have negative serum pregnancy test performed within 7-days prior to registration
• •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
• •Patient must sign a study-specific consent form prior to registration
• •Ability to understand and the willingness to sign a written informed consent; a signed informed consent must be obtained prior to any study specific procedures